[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100479429":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":29,"centralContacts":33,"locations":39,"responsibleParty":71,"collaborators":28,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":28,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":28,"enrollmentInfo":82,"targetDuration":28,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":28,"overallStatus":64,"whyStopped":28,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"SPARK Biopharma","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","OTHER","SB17170 initial dose: 300 mg\u002Fd per day, 3 to 6 subjects per cohort",[13],"Drug: SB17170",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","SB17170 dose: 600 mg\u002Fd per day, 3 to 6 subjects per cohort",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","SB17170 dose: 1000 mg\u002Fd per day, 3 to 6 subjects per cohort",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","SB17170","SB17170 capsules, Oral administration 21days\u002Fcycle",[9,15,19],null,[30],{"name":31,"affiliation":5,"role":32},"Soojin Jun","STUDY_DIRECTOR",[34],{"name":35,"role":36,"phone":37,"phoneExt":28,"email":38},"Sun Bin Kang","CONTACT","8228879905","sbkang@sparkbio.co.kr",[40,54,62],{"facility":41,"status":42,"city":43,"state":28,"zip":28,"country":44,"countryCode":28,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Asan Medical Center","NOT_YET_RECRUITING","Seoul","South Korea",{"type":46,"coordinates":47},"Point",[48,49],126.9784,37.566,{"lat":49,"lon":48},[52],{"name":53,"role":36,"phone":28,"phoneExt":28,"email":28},"Changhoon Yoo, M.D.",{"facility":55,"status":42,"city":43,"state":28,"zip":28,"country":44,"countryCode":28,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"Seoul National University Hospital",{"type":46,"coordinates":57},[48,49],{"lat":49,"lon":48},[60],{"name":61,"role":36,"phone":28,"phoneExt":28,"email":28},"Do-Youn Oh, M.D.",{"facility":63,"status":64,"city":43,"state":28,"zip":28,"country":44,"countryCode":28,"cosmosGeoPoint":65,"geoPoint":67,"contacts":68},"Severance Hospital","RECRUITING",{"type":46,"coordinates":66},[48,49],{"lat":49,"lon":48},[69],{"name":70,"role":36,"phone":28,"phoneExt":28,"email":28},"HyeJin Choi, M.D.",{"type":72,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100479429","phase-1-sb17170-phase-1-clinical-trial-in-solid-tumors-100479429",false,"NCT05522868","SB17170 Phase 1 Clinical Trial in Solid Tumors","An Open-label, Multicenter, Phase 1 Clinical Trial to Evaluate MTD, Safety, PK\u002FPD and Preliminary Anti-tumor Activity of SB17170 in Patients With Locally Advanced or Metastatic Solid Tumors Who Have Failed Standard of Care","Inclusion Criteria:\n\n* A patient with a histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors.\n* A person who has failed the known standard of care or has developed resistance to the standard of care and no longer has applicable standard of care\n* A patient with at least one measurable lesion according to the RECIST v1.1 criteria.\n* A person with Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.\n* Those with an expected survival period of 3 months or more at the discretion of of the investigator.\n\nExclusion Criteria:\n\n* A patient who has received drugs targeting High Mobility Group Box 1 (HMGB1).\n* A patient who has received or is undergoing chemotherapy (including chemotherapy, radiation therapy, immunotherapy, hormone therapy, targeted therapy, biological products, and tumor embolization) within 28 days from the first administration date of the investigational drug.\n* A person who needs to take contraindicated drugs or is expected to take them during the study period.","ALL","19 Years",{"count":83,"type":84},50,"ESTIMATED","INTERVENTIONAL",[87],"PHASE1","Phase 1 Open-label, multicenter, dose escalation, dose expansion study",[90],"Solid Tumor","2025-11-17",{"date":93,"type":94},"2025-11-20","ACTUAL",{"date":96,"type":94},"2022-10-17",{"date":98,"type":84},"2027-12-30",{"name":5,"class":6},3]